44 results about "Anticancer peptide" patented technology

Antimicrobial and anticancer peptides engineered using Gaegurin 5 isolated from Korean frog (Rana rugosa), which have a smaller structure compared with previously known Gaegurin peptides and show potent antimicrobial and anticancer activity. Specifically, the antimicrobial and anticancer peptides synthesized from the shortest length of Gaegurin 5, show potent antimicrobial activity against gram positive and negative strains, good safety with very low hemolytic activity and favorable advantages such as drug absorption and drug transportation due to its advantageous structural property, which can be useful as a potent antimicrobial or anticancer agent.

This invention provides new anticancer analogs of antimicrobial peptide temporin-SHa. New analogs (SEQ ID NOs: 2-6) of temporin SHa and, two different conjugates (7 & 8) comprising of monomeric and dimeric form of SEQ ID NO 4 with cancer targeting ligand were identified as anticancer peptides.

The invention relates to the biotechnology field, specifically relates to an improvement method of natural anticancer peptide. The method comprises the design improvements at two stages by use of natural polypeptide as a template; in the design improvement at the first stage, a series of polypeptide derivatives are obtained by changing the percentage of polypeptide net charge and the hydrophobic residue in the polypeptide; in the design improvement at the second stage, the variety and the number of the screened polypeptide amino acid residue are unchanged, only the primary amino acid sequence is changed, so that the alpha-helix in the high-level structure is located at different positions or disappeared to obtain the series of polypeptide again. The anticancer peptide prepared by use of the method disclosed by the invention is not only high in anticancer property, but also small in toxicity and safer to the human body.

The invention relates to a method for separating out a prostatic cancer (PC)-3 anticancer peptide by utilizing a thermal reactant of setipinna taty protein antibacterial peptide liquid and an anticancer peptide obtained by using the method. The method is characterized by comprising the following steps of (1), preparing setipinna taty protein antibacterial peptide liquid, regulating the pH value of the setipinna taty protein antibacterial peptide liquid to 5.0-7.0; (2), thermally treating the setipinna taty protein antibacterial peptide liquid, heating for 30 minutes-60 minutes in a sterilization pot of 100 DEG C-121 DEG C to prepare the thermal reactant of setipinna taty protein antibacterial peptide liquid; and (3), separating out the anticancer peptide from the thermal reactant of the setipinna taty protein antibacterial peptide liquid. Compared with the prior art, the method disclosed by the invention has advantages that setipinna taty protein antibacterial peptide liquid is taken as a starting substrate, and two-step gel separation is carried out, so that the prostatic cancer (PC)-3 anticancer peptide separated from the thermal reactant of the setipinna taty protein antibacterial peptide liquid has purity larger than 94%, is small in molecular weight and is easily absorbed by human body without easily causing anaphylactic reaction. The chemically synthesized peptide of the anticancer peptide shows dose-dependent characteristic for proliferation inhibition of the prostatic cancer (PC)-3 anticancer peptide, and has very obvious apoptosis-inducing effect on PC-3 tumor cells, and can block cell division in a period S.

The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof, as well as fusion peptides and pharmaceutical compositions comprising it; or, alternatively, the peptide or pharmaceutical salt thereof is one which has an amino acid sequence with an identity from 85% to 95% with respect to sequence SEQ ID NO: 25, 26, 27 or 28. The peptides of the invention show anticancer activity.

The present invention provides a peptide of formula (I) or a pharmaceutical salt thereof wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; and “r” is comprised from 1 to 10; a linker biradical of formula (II), which is connecting an alpha carbon atom of an amino acid located at position “i” in the peptide sequence of formula (I) with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence of formula (I); a C-terminal end corresponding to —C(O)R4; and a N-terminal end corresponding to —NHR5. The peptides of the invention show anticancer activity and an appropriate half-life and stability. Formula (I).

The invention discloses an antimicrobial fusion peptide. The peptide chain sequence of the antimicrobial fusion peptide is SISLLYGRKKRRQRRR. The invention further provides another antimicrobial fusionpeptide of which the peptide chain sequence is YGRKKRRQRRRSISLL. The invention provides a preparation method of the antibacterial fusion peptide. The preparation method comprises the following steps:coupling corresponding amino acids from the carbon terminal to the nitrogen terminal according to the sequence of a target antibacterial fusion peptide; washing and blowing deprotection groups to dryness after coupling of the nitrogen-terminated amino acid is completed; cutting, carrying out suction filtration and fully washing and centrifuging by using ice diethyl ether to remove supernatant forthree times or above; dissolving the dried solid powder by using deionized water, separating, purifying, collecting main peak effluent and carrying out freeze drying to obtain the target antimicrobial fusion peptide. The invention further discloses application of the antimicrobial fusion peptide in medicines. According to the preparation method disclosed by the invention, the fusion peptide withan antibacterial effect is obtained on the basis of anticancer peptide; in addition, the antibacterial effect of the antimicrobial fusion peptide is close to the antibacterial effect of a powerful antimicrobial drug kanamycin, so that a basis is provided for further research and development of drugs with dual effects of resisting cancer and bacteria.